tiprankstipranks
Trending News
More News >
Renalytix Plc OTC (GB:RENX)
:RENX
Advertisement

Renalytix (RENX) Price & Analysis

Compare
12 Followers

RENX Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

16.10%0.05%83.86%
16.10% Insiders
Mutual Funds
0.05% Other Institutional Investors
83.86% Public Companies and
Individual Investors

RENX FAQ

What was Renalytix Plc OTC’s price range in the past 12 months?
Renalytix Plc OTC lowest share price was 6.50p and its highest was 18.00p in the past 12 months.
    What is Renalytix Plc OTC’s market cap?
    Renalytix Plc OTC’s market cap is £24.01M.
      When is Renalytix Plc OTC’s upcoming earnings report date?
      Renalytix Plc OTC’s upcoming earnings report date is Nov 04, 2025 which is in 104 days.
        How were Renalytix Plc OTC’s earnings last quarter?
        Currently, no data Available
        Is Renalytix Plc OTC overvalued?
        According to Wall Street analysts Renalytix Plc OTC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Renalytix Plc OTC pay dividends?
          Renalytix Plc OTC does not currently pay dividends.
          What is Renalytix Plc OTC’s EPS estimate?
          Renalytix Plc OTC’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Renalytix Plc OTC have?
          Renalytix Plc OTC has 331,206,020 shares outstanding.
            What happened to Renalytix Plc OTC’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Renalytix Plc OTC?
            Currently, no hedge funds are holding shares in GB:RENX

            Company Description

            Renalytix Plc OTC

            Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

            RENX Earnings Call

            Q2 2025
            0:00 / 0:00
            Earnings Call Sentiment|Neutral
            The earnings call highlighted significant strategic achievements, including Medicare coverage developments, inclusion in clinical guidelines, successful fundraising, and cost reduction efforts. However, there are challenges such as a decline in revenue and testing volumes, and adoption hurdles in the VA system. The sentiment is balanced, with positive long-term strategic developments countered by short-term operational challenges.Read More>
            Similar Stocks
            Company
            Price & Change
            Follow
            ANGLE plc
            Craneware
            Sareum Holdings
            Kooth
            Arecor Therapeutics PLC
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis